Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Feasibility of Extracorporeal Delivery of Fusosomes to Generate CAR T Cells In Vivo

Jesse Green, Andrew Tucker, Aesha Vakil, Matt Scott-Skandera, Vasily Vagin, Dharmesh Dingar, Tarik Elgendi, Christina Proano, Brian Dolinski, Matthew A Lunning, Scott A Koepsell, Charles A Branson, Kerrie Enger, Danielle Quarles, Hosein Kouros-Mehr, Sarah Miller, Misha Shamashkin, Kutlu G Elpek

Blood (2023) 142 (Supplement 1): 3631.

https://doi.org/10.1182/blood-2023-186317

Published: 2023

Journal Articles

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Blood (2021) 137 (3): 323–335.

https://doi.org/10.1182/blood.2020006770

Published: 2021

Includes: Supplemental data

Journal Articles

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Jordan Gauthier, Alexandre V. Hirayama, Janaki Purushe, Kevin A. Hay, James Lymp, Daniel H. Li, Cecilia C. S. Yeung, Alyssa Sheih, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Tinh-Doan Phi, Rachel N. Steinmetz, Mazyar Shadman, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle

Blood (2020) 135 (19): 1650–1660.

https://doi.org/10.1182/blood.2019002936

Published: 2020

Includes: Supplemental data

Journal Articles

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

Evandro D. Bezerra, MD, Jordan Gauthier, MD MSc, Alexandre V. Hirayama, MD, Barbara S. Pender, MSc, Reed M. Hawkins, BS, Aesha Vakil, MSc, Rachel N. Steinmetz, BS, Aude G. Chapuis, MD, Brian G. Till, MD, Hans-Peter Kiem, MD PhD, Mazyar Shadman, MD MPH, Ryan D. Cassaday, MD, Stanley R. Riddell, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2019) 134 (Supplement_1): 201.

https://doi.org/10.1182/blood-2019-123807

Published: 2019

Journal Articles

High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy

Alexandre V. Hirayama, Jordan Gauthier, Kevin A. Hay, Jenna M. Voutsinas, Qian Wu, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Rachel N. Steinmetz, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle

Blood (2019) 134 (7): 636–640.

https://doi.org/10.1182/blood.2019000905

Published: 2019

Journal Articles

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Blood (2019) 133 (17): 1876–1887.

https://doi.org/10.1182/blood-2018-11-887067

Published: 2019

Includes: Supplemental data

Journal Articles

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Blood (2019) 133 (15): 1652–1663.

https://doi.org/10.1182/blood-2018-11-883710

Published: 2019

Includes: Supplemental data

Journal Articles

Impact of Intestinal Microbiota on Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Stem Cell Transplantation

Alyssa Sheih, PhD, Jonathan L. Golob, MD, PhD, Abir Bhattacharyya, MBBS, Michael C. Wu, PhD, Aesha Vakil, MSc, Sujatha Srinivasan, PhD, Steven A. Pergam, MD MPH, David N. Fredricks, MD, Cameron J. Turtle, MBBS, PhD

Blood (2018) 132 (Supplement 1): 3393.

https://doi.org/10.1182/blood-2018-99-115158

Published: 2018

Journal Articles

Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma

Jordan Gauthier, MD, Alexandre V. Hirayama, MD, Kevin A. Hay, MDFRCPC, MSc, Alyssa Sheih, PhD, Barbara S. Pender, MSc, Reed M. Hawkins, BS, Aesha Vakil, MSc, Tinh-Doan Phi, BS, Rachel N. Steinmetz, BS, Aude G. Chapuis, MD, Brian G. Till, MD, Hans-Peter Kiem, MD PhD, Mazyar Shadman, Ryan D. Cassaday, MD, Utkarsh H. Acharya, DO, Stanley R. Riddell, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2018) 132 (Supplement 1): 1415.

https://doi.org/10.1182/blood-2018-99-111528

Published: 2018

Journal Articles

Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 1680.

https://doi.org/10.1182/blood-2018-99-116745

Published: 2018

Journal Articles

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 1681.

https://doi.org/10.1182/blood-2018-99-115126

Published: 2018

Journal Articles

Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival

Blood (2018) 132 (Supplement 1): 281.

https://doi.org/10.1182/blood-2018-99-110561

Published: 2018

Journal Articles

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

Blood (2018) 132 (Supplement 1): 299.

https://doi.org/10.1182/blood-2018-99-111061

Published: 2018

NARROW

Feasibility of Extracorporeal Delivery of Fusosomes to Generate CAR T Cells In Vivo

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Impact of Intestinal Microbiota on Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Stem Cell Transplantation

Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma

Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only